Examples of 'dinutuximab' in a sentence
Meaning of "dinutuximab"
dinutuximab (noun) - Dinutuximab is a monoclonal antibody drug used in the treatment of neuroblastoma, a type of cancer that mostly affects children
Show more definitions
- A particular monoclonal antibody
How to use "dinutuximab" in a sentence
Basic
Advanced
dinutuximab
The effects of dinutuximab on fertility in humans are unknown.
Unituxin contains the active substance dinutuximab.
No cases of dinutuximab beta overdose have been reported.
Treatment with opioids is standard with dinutuximab beta.
Last dose of dinutuximab for that course.
Dinutuximab was administered at a dose equivalent to.
It is unknown whether dinutuximab beta is excreted in human milk.
Regular monitoring of liver function is recommended during dinutuximab immunotherapy.
Dinutuximab can cause neuropathic pain during and after infusion.
The active substance is dinutuximab beta.
Dinutuximab beta has major influence on the ability to drive and use machines.
There are no data from the use of dinutuximab in pregnant women.
Unituxin is a cancer medicine that contains the active substance dinutuximab.
Eye disorders may occur as dinutuximab beta binds to optic nerve cells.
The medicine contains the active substance dinutuximab beta.
See also
Treatment with dinutuximab beta should be permanently discontinued if the following toxicities occur,.
There is insufficient information on the excretion of dinutuximab in human milk.
Calculations of pharmacokinetic parameters for dinutuximab beta are based upon measurements using non-validated bioanalytical methods.
Patients should not use or drive machines during treatment with dinutuximab beta.
Recommended dose modifications for dinutuximab beta Adverse reaction Severity.
Hepatic dysfunction Regular monitoring of liver function is recommended during dinutuximab immunotherapy.
Dinutuximab binds to the GD2 and causes the cell to breakdown and die.
Dose modification of dinutuximab beta.
Dinutuximab beta receives positive recommendation for the treatment of high-risk neuroblastoma in Europe.
If tolerated without worsening symptoms, administer dinutuximab at.
Dinutuximab alone for subsequent GM-CSF courses.
If tolerated without worse i symptoms, administer dinutuximab at.
Qarziba contains dinutuximab beta, which belongs to a group of medicines called ‘ monoclonal antibodies '.
Intravenous ( IV ) fluids will be administered prior to the infusion of dinutuximab.
Treatment with dinutuximab beta consists of 5 consecutive courses, each course comprising 35 days.
What Unituxin contains - The active substance is dinutuximab.
Dinutuximab ( Unituxin ) is used for the treatment of neuroblastoma.
First 5-day treatment should start 7 days prior to first dinutuximab beta infusion.
Maintain tolerated dinutuximab infusion rate for all subsequent courses with GM-CSF or IL-2.
Severe allergic reactions are more likely when dinutuximab is co-administered with IL-2.
Among subjects receiving dinutuximab immunotherapy plus isotretinoin and isotretinoin alone, respectively log-rank test p 0.0165.
Capillary leak syndrome is more likely when dinutuximab is co-administered with IL-2.
Unituxin 3.5 mg / mL concentrate for solution for infusion dinutuximab.
Proceed with subsequent planned dinutuximab and GM-CSF or IL-2 courses.
Each mL of concentrate contains 3.5 mg of dinutuximab.
If symptoms resolve the following day, resume dinutuximab at tolerated rate without GM-CSF or IL-2.
Qarziba 4.5 mg / mL concentrate for solution for infusion dinutuximab beta.
Immediately discontinue dinutuximab and intravenous GM-CSF or IL - 2.
However, the presence of HACA appears to increase the clearance of dinutuximab by approximately 60.
Discontinue dinutuximab and GM-CSF or IL-2 for remainder of course.
If capillary leak syndrome occurred during GM-CSF course, administer dinutuximab alone for subsequent GM-CSF courses.
Dinutuximab beta Apeiron was designated as an orphan medicinal product on 8 November 2012.
Subsequently, a dosing rate of 0.03 mg / kg / hour is recommended concomitantly with dinutuximab beta infusion.
Phase 1/2 clinical trial, Dinutuximab as part of initial treatment.
The patient should be primed with 10 mg / kg / day, starting 3 days prior to dinutuximab beta infusion.
